TxCell receives EU Orphan Drug Designation for Col-Treg in the treatment of non-infectious uveitis
"Obtaining orphan drug designation for Col-Treg in the European Union is a recognition of the therapeutic potential of Col-Treg in autoimmune uveitis. Whilst this is a rare disease, it is a leading cause of blindness in the developed world. TxCell estimates around 30,000 autoimmune uveitis patients per year in the US and EU alone, for whom existing treatments do not work, could benefit significantly from the development of Col-Treg," said Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell. "We are moving rapidly to undertake a placebo-controlled, dose-ranging proof of principle clinical study in autoimmune uveitis. This is planned to start in the first half of 2015. The top line results of this study are expected mid-2016."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.